Theravance Biopharma (NASDAQ:TBPH) Cut to Hold at Wall Street Zen

Wall Street Zen downgraded shares of Theravance Biopharma (NASDAQ:TBPH) from a buy rating to a hold rating in a research note published on Saturday.

TBPH has been the topic of a number of other reports. HC Wainwright boosted their price objective on shares of Theravance Biopharma from $20.00 to $27.00 and gave the company a “buy” rating in a report on Monday, March 2nd. Oppenheimer lowered Theravance Biopharma from an “outperform” rating to a “market perform” rating in a research note on Thursday, March 5th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Theravance Biopharma in a research report on Thursday, January 22nd. B. Riley Financial reiterated a “neutral” rating and set a $14.00 price target (down from $28.00) on shares of Theravance Biopharma in a research note on Wednesday, March 4th. Finally, BTIG Research reissued a “buy” rating and issued a $21.00 price objective on shares of Theravance Biopharma in a report on Friday. Two analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $21.33.

Theravance Biopharma Trading Up 2.9%

NASDAQ:TBPH opened at $14.75 on Friday. Theravance Biopharma has a twelve month low of $7.90 and a twelve month high of $21.03. The company has a market cap of $747.38 million, a PE ratio of 7.27 and a beta of 0.17. The company’s 50 day moving average is $17.91 and its two-hundred day moving average is $16.89.

Insider Buying and Selling at Theravance Biopharma

In other news, SVP Rhonda Farnum sold 31,067 shares of the stock in a transaction on Monday, March 16th. The shares were sold at an average price of $13.96, for a total value of $433,695.32. Following the sale, the senior vice president owned 232,699 shares in the company, valued at $3,248,478.04. This represents a 11.78% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 6.90% of the stock is owned by insiders.

Institutional Investors Weigh In On Theravance Biopharma

Hedge funds have recently added to or reduced their stakes in the business. Arrowstreet Capital Limited Partnership purchased a new position in shares of Theravance Biopharma during the 3rd quarter valued at about $10,611,000. Assenagon Asset Management S.A. boosted its stake in shares of Theravance Biopharma by 1,629.4% in the third quarter. Assenagon Asset Management S.A. now owns 414,715 shares of the biopharmaceutical company’s stock worth $6,055,000 after buying an additional 390,735 shares during the last quarter. Pacer Advisors Inc. acquired a new stake in Theravance Biopharma during the fourth quarter worth about $6,342,000. Hillsdale Investment Management Inc. acquired a new stake in Theravance Biopharma during the third quarter worth about $4,536,000. Finally, Janus Henderson Group PLC raised its position in Theravance Biopharma by 214.8% during the fourth quarter. Janus Henderson Group PLC now owns 400,496 shares of the biopharmaceutical company’s stock valued at $7,493,000 after acquiring an additional 273,288 shares in the last quarter. 99.10% of the stock is owned by hedge funds and other institutional investors.

Theravance Biopharma Company Profile

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.